Pathophysiology and immunology of allergic bronchopulmonary aspergillosis

Area of Science:

• Pulmonology
• Immunology
• Mycology

Background:

• Allergic bronchopulmonary aspergillosis (ABPA) is a significant complication in patients with persistent asthma and cystic fibrosis (CF).
• These conditions involve excessive mucus production and impaired mucociliary clearance, facilitating Aspergillus fumigatus persistence and germination.
• Fungal products from Aspergillus fumigatus exacerbate airway compromise and initiate immune responses.

Purpose of the Study:

• To elucidate the immunological and clinical characteristics of Allergic bronchopulmonary aspergillosis.
• To identify key factors contributing to susceptibility and disease manifestation in ABPA.
• To outline current therapeutic strategies and essential monitoring parameters for ABPA management.

Main Methods:

• Review of existing literature on the pathogenesis, immunology, and clinical presentation of ABPA.
• Analysis of the role of Aspergillus fumigatus allergens and host immune factors (e.g., cytokines, genetic predisposition).
• Examination of diagnostic criteria, clinical manifestations, and treatment outcomes, including serologic markers like IgE.

Main Results:

• ABPA pathogenesis involves chemokine-mediated recruitment of A. fumigatus-specific TH2 lymphocytes and is influenced by immunogenetic factors.
• Key features include eosinophilia, elevated specific IgG, IgA, and IgE antibodies, and a marked increase in total IgE.
• Clinical manifestations include recurrent asthma exacerbations, pulmonary infiltrates, and central bronchiectasis, potentially leading to fibrosis.

Conclusions:

• ABPA is a complex hypersensitivity reaction to Aspergillus fumigatus, particularly in individuals with asthma and CF.
• Effective management hinges on systemic glucocorticoids, azoles, and diligent monitoring of clinical, radiographic, and serologic parameters, with a focus on total IgE levels.